Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines

Kloudová, Kamila; Hromadkova, Hana; Partlová, Simona; Brtnicky, Tomas; Rob, Lukáš; Bartůňková, Jiřina; Hensler, Michal; Halaška, Michael; Špíšek, Radek; Fialová, Alena

doi:10.18632/oncotarget.10028

Cited by 33 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of agents, such as PD-1-specific monoclonal antibodies to block inhibitory pathways downstream of antigen recognition (Keytruda, Merck) or personalized therapeutic vaccines aimed at reprogramming the immune system against cancer (Sipuleucel-T, Dendreon), have acquired FDA approval in the treatment of lung and prostate cancers, respectively (8,9). Although no FDA-approved immunotherapy for ovarian cancer exists, research correlating increased progressionfree survival with greater influx of T cells in tumors of patients with advanced ovarian carcinoma, and the emergence of epithelial ovarian cancer (EOC)-associated antigens, reflect the candidacy of EOC for immune-based treatments (10,11).…”

Section: Introductionmentioning

confidence: 99%

Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer

Matuszewska

Santry

Vloten

et al. 2019

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer

Matuszewska

Santry

Vloten

et al. 2019

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…The expressed fusion protein is highly selective, site-specific, and versatile due to its high affinity for an array of BG substrates, e.g. toxins, fluorophores or photosensitizers [6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66]. The conjugation of photosensitizers to SNAP-tag has made it an indispensable tool in photoimmunotherapy.…”

Section: Antibody-drug Conjugates and Fusion Proteins In Breast And Omentioning

confidence: 99%

“…Recently, the cancer-testis antigen NY-ESO-1 was discovered to be one of the few tumor-associated antigens (TAAs) that have restricted expression in normal tissue but was aberrantly expressed in epithelial ovarian cancers [12]. More than 90% of tumor samples expressed very high levels of CA125, FOLR1, EPCAM, and MUC-1 on both primary and established ovarian cancer cell lines [13]. By screening for these TAAs in cancerous cell lines or tissues and targeting them with SNAP fusions, the appropriate treatment modality can be employed.…”

Section: Introductionmentioning

confidence: 99%

Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer

Padayachee

Biteghe

Malindi

et al. 2017

Transfus Med Hemother

View full text Add to dashboard Cite

Considerable research efforts have been dedicated to understanding ovarian and breast cancer mechanisms, but there has been little progress translating the research into effective clinical applications. Hence, personalized/precision medicine has emerged because of its potential to improve the accuracy of tumor targeting and minimize toxicity to normal tissue. Targeted therapy in both breast and ovarian cancer has focused on antibodies, antibody drug conjugates (ADCs), and very recently the introduction of human antibody fusion proteins. Small molecule inhibitors and monoclonal antibodies (mAbs) are used in conjunction with chemotherapeutic drugs as a form of treatment but problems arise from a board expression of the target antigen in healthy tissues. Also, insufficient tumor penetration due to tight binding affinity and macromolecular size of mAbs compromise the efficacy of these ADCs. A more targeted approach is thus needed, and ADCs were designed to meet this need. However, in ADCs the method of conjugation of drug to antibody is >1, altering the structure of the drug which leads to off-target effects. Random conjugation also causes the drug to affect the pharmokinetics and biodistribution of the antibody and may cause nonspecific binding and internalization. Recombinant therapeutic proteins achieve controlled conjugation reactions and combine cytotoxicity and targeting in one molecule. They can also be engineered to extend half-life, stability and mechanism of action, and offer novel delivery routes. SNAP-tag fusion proteins are an example of a theranostic recombinant protein as they provide a unique antibody format to conjugate a variety of benzyl guanine modified labels, e.g. fluorophores and photosensitizers in a 1:1 stoichiometry. On the one hand, SNAP tag fusions can be used to optically image tumors when conjugated to a fluorophore, and on the other hand the recombinant proteins can induce necrosis/apoptosis in the tumor when conjugated to a photosensitizer upon exposure to a changeable wavelength of light. The dual nature of SNAP-tag fusions as both a diagnostic and therapeutic tool reinforces its significant role in cancer treatment in an era of precision medicine.

show abstract

“…journals.viamedica.pl/ginekologia_polska Thanks to these properties it is very good material for studies on new formulas, medications and compounds. OVCAR 3 includes cancer cells that are highly aggressive.The cells: OVCAR 3 and CAOV 3 show expression of CA125 [28,29]. OVCAR 3 and CAOV3 are both used as a cell model to study cisplatin [30,31].…”

Section: Cell Culturementioning

confidence: 99%

Anticancer activity of a trans-platinum(II) complex of 3-aminoflavone to ovarian cancer cells

Orzechowska

Fabijańska²,

Ochocki³

et al. 2017

Ginekol Pol

View full text Add to dashboard Cite

Objectives: Cisplatin is a classical anticancer drug used in the treatment of ovarian cancer. Unfortunately, the treatment is associated with numerous adverse effects. Studies concerning new platinum derivatives with less organ toxicity are conducted. The aim of this study was to analyse the effect of a new trans-platinum(II) complex of 3-aminoflavone on the viability and mortality of the cells from OVCAR 3 and CAOV 3 ovarian cancer cell lines and on the expression of the selected genes involved in the process of apoptosis. Material and methods:The viability of ovarian cancer cells and the cytotoxicity of a trans-platinum(II) complex of 3-aminoflavone: [trans-Pt(3-af ) 2 Cl 2 ), trans-bis-(3-aminoflavone) dichloridoplatinum(II)] and cisplatin were analysed using a spectrophotometric method with the use of MTT assay and LDH assay. BAX, BCL2, BIRC5 gene expression analysis on mRNA level was conducted with the use of Real-Time PCR method.Results: It was observed that parallel to an increase in the concentration of the new complex compound and cisplatin there is a decrease in viability and an increase in mortality of ovarian cancer cells. As a result of exposure to the studied compound and cisplatin, an increased BAX gene expression and decreased BCL2 and BIRC5 gene expression were observed in the studied ovarian cancer cell lines. Conclusion:Trans-Pt(3-af ) 2 Cl 2 exhibits anticancer activity towards OVCAR 3 and CAOV 3 ovarian cancer cell lines. The studied complex compound can be considered as a potential anticancer drug.

show abstract

Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines

Cited by 33 publications

References 15 publications

Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer

Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer

Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer

Anticancer activity of a trans-platinum(II) complex of 3-aminoflavone to ovarian cancer cells

Contact Info

Product

Resources

About